Nasdaq

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
Nasdaq

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication

GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes ...
Seeking Alpha

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and ...
Fox2Now St. Louis

Study of More Than 18,000 Patients Finds Exome Sequencing Delivers Higher Diagnostic Rates for Autism Spectrum Disorders

GAITHERSBURG, Md., April 26, 2022 /PRNewswire/ -- GeneDx, LLC, a leader in genomic analysis, today unveiled new data demonstrating positive outcomes of exome analysis for individuals with autism ...
KELOLAND News

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
Business Wire

Ambry Genetics Reports Specific Results from Clinical Diagnostic Exome™ Testing of Patients at Kennedy Krieger Institute

ALISO VIEJO, Calif. & BALTIMORE--(BUSINESS WIRE)--Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces specific results from one of three ...
Seeking Alpha

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

The Patient Access Program helps to ensure more equitable care across pediatric epilepsy populations. Exome testing is recommended as a first-line test for patients with unexplained epilepsy by the ...